Brief: Summit Therapeutics To Offer And Sell Common Stock Up To $380 Million Aggregate Through Sales Agent - SEC Filing
23/07/2026 22:42
BRIEF-Summit Therapeutics To Offer And Sell Common Stock Up To $380 Million Aggregate Through Sales Agent - SEC Filing July 23 (Reuters) - Summit Therapeutics Inc SMMT.O:
SUMMIT THERAPEUTICS - TO OFFER AND SELL COMMON STOCK UP TO $380 MILLION AGGREGATE THROUGH SALES AGENT - SEC FILING
Source text: [ID:n0001193125-26-314210]
Further company coverage: SMMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Summit Therapeutics
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
Brief: Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma
Factbox: Major drugmakers turn to China for licensing deals
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (updated)